Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Bramstedt – page 71

1 461 clinical trials in Bad Bramstedt, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Bramstedt at a glance
1 461
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 461 trials in Bad Bramstedt

Open in trial search

Efficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Exelixis Inc.

Study on Estriol Vaginal Ring for Treating Vaginal Atrophy in Postmenopausal Women

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Estriol
  • Sponsor:SocraTec R&D Concepts in Drug Research and Development GmbH

Study on the Safety and Immune Response of a Booster Dose of MenACYW Conjugate Vaccine in Children and Adolescents Previously Vaccinated for Meningococcal Infection

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · Healthy volunteers
  • Substances:Tetanus toxoid
  • Sponsor:Sanofi Winthrop Industrie

Study Comparing Zimberelimab and Domvanalimab with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Untreated Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Gilead Sciences Inc.

Study of BI 690517 and empagliflozin combination for protection of heart and kidneys in patients with chronic kidney disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Arteriosclerosis+2

Not recruiting

Long-term Safety Study of INZ-701 for Patients with ENPP1 and ABCC6 Deficiencies, Including Pseudoxanthoma Elasticum and Generalized Arterial Calcification of Infancy

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
  • Sponsor:Inozyme Pharma Inc.

Hyperlipidaemia

Not recruiting

Study on Lowering Cholesterol with Rosuvastatin or Rosuvastatin/Ezetimibe in Patients at High or Very High Risk of Cardiovascular Disease with High Cholesterol

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ezetimibe
  • Sponsor:KRKA tovarna zdravil d.d. Novo mesto

Type 1 diabetes mellitus+2

Not recruiting

Efficacy and Safety of Tirzepatide Versus Placebo in Adults with Type 1 Diabetes and Obesity or Overweight: A Phase 3 Randomized Controlled Trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tirzepatide
  • Sponsor:Eli Lilly & Co.

Vasoconstriction

Not recruiting

Evaluation of topical clascoterone versus drug combination for skin vasoconstriction in healthy volunteers

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · Healthy volunteers
  • Substances:Clascoterone
  • Sponsor:Cassiopea S.p.A.

Cardiac amyloidosis

Not recruiting

Efficacy and safety of eplontersen sodium plus ALXN2220 in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ALXN2220
  • Sponsor:AstraZeneca AB

Conjunctivitis allergic+1

Not recruiting

Dose‑finding trial of a mannan‑conjugated Phleum pratense/Dactylis glomerata allergoid vaccine in patients with grass‑pollen allergic rhinitis or rhinoconjunctivitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Bilastine
  • Sponsor:Inmunotek S.L.

Skin wrinkling

Not recruiting

Corabotase for Moderate to Severe Glabellar Lines in Adults

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum, Neurotoxin Serotype A/B
  • Sponsor:Ipsen Innovation

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Bramstedt

What the registry says about research in the country

01 Autoimmune Disorders

Innovative research focusing on systemic sclerosis treatment, investigating a novel subcutaneous therapy aimed at reducing skin sclerosis symptoms. These trials are evaluating new therapeutic approaches for managing this challenging autoimmune condition.

  • Skin sclerosis management
  • Subcutaneous administration methods
  • Novel therapeutic compounds

The research emphasizes improving treatment options for patients with progressive skin hardening and tissue fibrosis.

02 Rare Blood Disorders

Clinical investigations targeting Hypereosinophilic Syndrome, examining the effectiveness of new subcutaneous treatments for patients with uncontrolled disease states while maintaining standard care protocols.

  • Blood disorder management
  • Treatment resistance
  • Standard of care optimization

These studies aim to provide better therapeutic options for patients with rare eosinophilic conditions.

03 Inflammatory Conditions

Advanced research into systemic lupus erythematosus treatment, focusing on disease activity reduction and exploring new therapeutic compounds for this complex autoimmune disorder.

  • Disease activity assessment
  • Treatment safety evaluation
  • Long-term efficacy monitoring

The studies employ comprehensive assessment tools to measure treatment effectiveness in lupus patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.